Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Michaeli

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 1998
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cellsD S Siegel, X Zhang, R Feinman, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2001
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progressionR N Pearse, E M Sordillo, S Yaccoby, et al.
Blood|November 15, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agentM Andreeff, R Stone, J Michaeli, et al.
Blood|August 26, 1998
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myelomaP H Rao, J C Cigudosa, Y Ning, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 1998
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cellsD S Siegel, X Zhang, R Feinman, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2001
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progressionR N Pearse, E M Sordillo, S Yaccoby, et al.
Blood|November 15, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agentM Andreeff, R Stone, J Michaeli, et al.
Blood|August 26, 1998
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myelomaP H Rao, J C Cigudosa, Y Ning, et al.
Pageof 7